Protara Therapeutics, Inc. TARA
Regular-session close
After hours · Nov 16, 4:41 PM ET
- YTD
- -55.35%
- 1 year
- -56.81%
- Market cap
- 146.54M
- EPS (ttm)
- -1.39
- Shares out
- 34.32M
- Forward P/E
- -1.61
- YTD return
- -55.35%
- 1-year return
- -56.81%
- 50-day average
- 3.22
- 200-day average
- 2.74
- Enterprise value
- -31.37M
- Volume
- 631.32K
- Avg volume
- 1.02M
- Open
- 2.52
- Previous close
- 2.53
- Day's range
- 2.36 – 2.52
- 52-week range
- 2.09 – 7.82
- Beta
- 1.79
- Analysts
- Strong Buy
- Price target
- 26.40 (+1009.2%)
Key statistics
- Price / book
- 0.86
- Free cash flow
- -20.31M
- Total cash
- 89.58M
- Total debt
- 4.98M
- Return on equity
- -45.91%
- Short % of float
- 17.65%
Fundamental scorecard
3 of 25 checks passed on TARA’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.50 | -0.50 | 0.00 | 0.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.82 | -0.45 | +0.37 | +45.12% |
| May 2, 2024 | Mar 1, 2024 | -0.99 | -0.97 | +0.02 | +2.02% |
| Mar 13, 2024 | Dec 1, 2023 | -1.03 | -0.90 | +0.13 | +12.62% |
| Nov 3, 2023 | Sep 1, 2023 | -1.10 | -0.87 | +0.23 | +20.91% |
| Aug 3, 2023 | Jun 1, 2023 | -0.97 | -1.00 | -0.03 | -3.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Guggenheim | reit | Buy | Buy |
| Dec 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protaratx.com
News
Your note
Sign in to keep a note on TARA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BANDARI JATHIN | Officer | Stock Award(Grant) | Jan 18, 2024 | 56,704 |
| FABBIO PATRICK | Chief Financial Officer | Stock Award(Grant) | Jan 18, 2024 | 22,000 |
| FRY HANNAH | Officer | Stock Award(Grant) | Jan 18, 2024 | 29,836 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 0 |
| SHEFFERMAN JESSE M | Chief Executive Officer | Stock Gift | Aug 27, 2024 | 935,501 |
| ZUMMO JACQUELINE | Officer | Stock Award(Grant) | Jan 18, 2024 | 104,296 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.21% | 1,900,000 | 9.79M | Sep 29, 2024 |
| Opaleye Management Inc. | 8.15% | 1,681,154 | 8.66M | Sep 29, 2024 |
| Stempoint Capital LP | 4.57% | 942,857 | 4.86M | Sep 29, 2024 |
| Woodline Partners LP | 4.13% | 851,567 | 4.39M | Sep 29, 2024 |
| Boxer Capital, LLC | 3.93% | 811,627 | 4.18M | Sep 29, 2024 |
| Vanguard Group Inc | 3.68% | 759,612 | 3.91M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 616,301 | 3.17M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.68% | 140,668 | 724.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 97,351 | 501.36K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 49,200 | 253.38K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.20% | 41,236 | 212.37K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 30,335 | 156.22K | Oct 30, 2024 |
